Casgevy commercialization ramps up: Social media discussions spotlight CRISPR Therapeutics' Casgevy therapy, now generating substantial revenue after approval, with over $116 million booked in 2025. Users note the expansion to more than 75 treatment centers alongside partner Vertex, positioning it as a leader in gene editing. Optimism surrounds its potential to cure previously untreatable diseases.
Pipeline draws investor focus: Conversations highlight the company's oncology pipeline and early cardiovascular programs targeting huge markets like cholesterol disorders. High-risk profiles are acknowledged, yet visions of 10x gains and massive upside prevail among enthusiasts. ARK Invest's top weighting in its flagship ETF reinforces long-term bets.
Amid recent plunge, bulls persist: Following an 11% stock drop, traders eye technical breakouts toward $150 and fresh buy ratings with $65 targets. Regulatory hurdles and budget pressures are flagged, but revenue traction from Casgevy bolsters resolve. Sentiment tilts bullish on innovation momentum.
Note: This discussion summary was generated from an AI condensation of post data.
CRISPR Therapeutics Insider Trading Activity
CRISPR Therapeutics insiders have traded $CRSP stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $CRSP stock by insiders over the last 6 months:
- SAMARTH KULKARNI (Chief Executive Officer) has made 0 purchases and 7 sales selling 127,134 shares for an estimated $7,018,135.
- RAJU PRASAD (Chief Financial Officer) has made 0 purchases and 10 sales selling 88,249 shares for an estimated $5,100,887.
- JAMES R. KASINGER (General Counsel and Secretary) has made 0 purchases and 4 sales selling 11,544 shares for an estimated $574,239.
- NAIMISH PATEL (Chief Medical Officer) sold 3,150 shares for an estimated $152,019
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
CRISPR Therapeutics Hedge Fund Activity
We have seen 217 institutional investors add shares of CRISPR Therapeutics stock to their portfolio, and 188 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,437,220 shares (-43.8%) from their portfolio in Q4 2025, for an estimated $75,367,816
- ORBIS ALLAN GRAY LTD added 968,060 shares (+19.4%) to their portfolio in Q4 2025, for an estimated $50,765,066
- ARK INVESTMENT MANAGEMENT LLC added 735,084 shares (+7.5%) to their portfolio in Q4 2025, for an estimated $38,547,804
- MORGAN STANLEY removed 730,799 shares (-52.3%) from their portfolio in Q4 2025, for an estimated $38,323,099
- SQUAREPOINT OPS LLC added 581,108 shares (+inf%) to their portfolio in Q4 2025, for an estimated $30,473,303
- TWO SIGMA INVESTMENTS, LP removed 574,068 shares (-55.0%) from their portfolio in Q4 2025, for an estimated $30,104,125
- BLACKROCK, INC. added 458,033 shares (+6.5%) to their portfolio in Q4 2025, for an estimated $24,019,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
CRISPR Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $CRSP in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/13/2026
- Citizens issued a "Market Outperform" rating on 01/30/2026
- Citigroup issued a "Buy" rating on 11/12/2025
To track analyst ratings and price targets for CRISPR Therapeutics, check out Quiver Quantitative's $CRSP forecast page.
CRISPR Therapeutics Price Targets
Multiple analysts have issued price targets for $CRSP recently. We have seen 10 analysts offer price targets for $CRSP in the last 6 months, with a median target of $76.5.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $110.0 on 03/17/2026
- Geulah Livshits from Chardan Capital set a target price of $76.0 on 02/17/2026
- Gil Blum from Needham set a target price of $82.0 on 02/13/2026
- Tyler Van Buren from TD Cowen set a target price of $45.0 on 02/13/2026
- Liisa Bayko from Evercore ISI Group set a target price of $74.0 on 02/13/2026
- Silvan Turkcan from Citizens set a target price of $80.0 on 01/30/2026
- Yigal Nochomovitz from Citigroup set a target price of $77.0 on 11/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
